Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by Stylesson Aug 28, 2013 11:22am
255 Views
Post# 21703410

RE:RE:RE:RE:RE:Epuris= why styless is vindictive towards cipher and sold at $6...LOL

RE:RE:RE:RE:RE:Epuris= why styless is vindictive towards cipher and sold at $6...LOLabsolutely right. The threat of a possible to war has everyone jittery right now.

Guess what stocks perform best in the face of a potential war situation?
Pharmas.

Pharmas are relatively immune to these types of world threats. Institutions flood to pharma stocks for safety in uncertain times. There business' are unaffected by war in the middle east. Also, historically, stocks rebound quite well after a sell off induced by the threat of war. 

6.50 is unlikely to occur. That's just where DND's 50 day moving average sits (provides a theoretical downside scenario).

I think you can see below 8 bucks which would be a nice place to add some more shares. 8.46 is too rich for adding to your position or build a new position in my view.
Bullboard Posts